Home > Gastroenterology > ECCO 2020 > Big Data Analysis > The positive impact of genetic data on drug development

The positive impact of genetic data on drug development

Presented By
Prof. S. Vermeire, University Hospital Leuven, Belgium
ECCO 2020
In a presentation about the International IBD Genetics Consortium (IIBDGC), Prof. Séverine Vermeire (University Hospital Leuven, Belgium) explained the focus and achievements of this consortium, which is open to any group that wishes to join. By collecting large datasets from countries from all over the world, the IIBDGC unravelled a total of about 240 significant inflammatory bowel disease (IBD)-associated single-nucleotide polymorphisms (SNPs) in multiple large genome-wide association studies (GWAS). This has yielded some 200 IBD loci, Prof. Vermeire explained. The newly identified loci have helped to much better understand the roles of the innate and acquired immune systems in the pathophysiology of IBD. Prof. Vermeire also highlighted the importance of genetic data on the development of new drugs. She noted that >25% of drugs that enter the clinical development stage fail to reach t...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on